Actively Recruiting
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
Led by M.D. Anderson Cancer Center · Updated on 2026-02-18
8
Participants Needed
1
Research Sites
98 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
CONDITIONS
Official Title
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female subjects 18 years of age or older
- History of allogeneic hematopoietic stem cell transplantation
You will not qualify if you...
- Receiving an investigational treatment for graft-versus-host disease within 28 days before study entry
- Active acute graft-versus-host disease
- Taking medications known to induce CYP3A4 enzyme activity
- Pregnant women
- Non-viable neonates
- Patients with cognitive impairments
- Patients younger than 18 years old
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
A
Amin Alousi, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here